EP2298783 - Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 12.10.2018 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 03.11.2017 | ||
Former | Grant of patent is intended Status updated on 04.07.2017 | ||
Former | Examination is in progress Status updated on 25.11.2016 | Most recent event Tooltip | 26.06.2020 | Lapse of the patent in a contracting state New state(s): CY | published on 29.07.2020 [2020/31] | Applicant(s) | For all designated states Yale University Two Whitney Avenue New Haven, CT 06510 / US | For all designated states Cheng, Yung-Chi 961 Baldwin Rd. Woodbridge, CT 06525 / US | For all designated states Tanaka, Hiromichi 3-7-1006 Ohdana-Nishi, Tsuzuki-ku Yokohama 224-0028 / JP | [2017/49] |
Former [2011/12] | For all designated states Yale University Two Whitney Avenue New Haven, CT 06511 / US | ||
For all designated states Cheng, Yung-Chi 961 Baldwin Rd. Woodbridge, CT 06525 / US | |||
For all designated states Tanaka, Hiromichi 3-7-1006 Ohdana-Nishi, Tsuzuki-ku Yokohama 224-0028 / JP | Inventor(s) | 01 /
Cheng, Yung-Chi 961 BALDWIN RD. WOODBRIDGE, CT 06525 / US | 02 /
Tanaka, Hiromichi 3-7-1006 OHDANA-NISHI, TSUZUKI-KU YOKOHAMA 224-0028 / JP | 03 /
Baba, Masanori 3-54-19 KOUTOKUJIDAI KAGOSHIMA Fukuoka 891-0103 / JP | [2017/49] |
Former [2011/12] | 01 /
Cheng, Yung-Chi 961 BALDWIN RD. WOODBRIDGE, CT 06525 / US | ||
02 /
Tanaka, Hiromichi 3-7-1006 OHDANA-NISHI, TSUZUKI-KU YOKOHAMA 224-0028 / JP | |||
03 /
Baba, Masanori 3-54-19 KOUTOKUJIDAI KAGOSHIMA Fukuoka 891-0103 / JP | Representative(s) | Dall'Olio, Giancarlo, et al Invention S.r.l. Via delle Armi 1 40137 Bologna / IT | [2017/49] |
Former [2011/12] | Dall'Olio, Giancarlo, et al Invention S.r.l. Via delle Armi 1 40137 Bologna / IT | Application number, filing date | 10155533.2 | 18.02.2004 | [2011/12] | Priority number, date | US20030448554 | 19.03.2003 Original published format: US 448554 | [2011/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2298783 | Date: | 23.03.2011 | Language: | EN | [2011/12] | Type: | B1 Patent specification | No.: | EP2298783 | Date: | 06.12.2017 | Language: | EN | [2017/49] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 11.01.2011 | Classification | IPC: | C07H19/10, A61K31/7068, A61P31/18 | [2011/12] | CPC: |
C07D405/04 (EP,US);
C07H19/10 (EP,KR,US);
A61K31/522 (EP,US);
A61K31/675 (EP,US);
A61K31/7072 (EP,US);
A61K31/7076 (EP,KR,US);
A61P31/12 (EP);
A61P31/14 (EP);
A61P31/18 (EP);
A61P31/22 (EP);
A61P37/04 (EP);
A61P43/00 (EP);
C07H19/06 (EP,US);
C07H19/14 (KR);
C07H19/16 (EP,KR,US);
| C-Set: |
A61K31/522, A61K2300/00 (EP,US);
A61K31/675, A61K2300/00 (US,EP);
A61K31/7072, A61K2300/00 (US,EP);
A61K31/7076, A61K2300/00 (US,EP) | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2017/49] |
Former [2011/12] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR | Title | German: | Antivirale Nukleosid-Analoga und Verfahren zur Behandlung von Virusinfektionen, insbesondere HIV-Infektionen | [2011/12] | English: | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | [2011/12] | French: | Analogues de nucléoside anti-viraux et procédé pour le traitement d'infections virales, en particulier des infections par VIH | [2011/12] | Examination procedure | 22.09.2011 | Amendment by applicant (claims and/or description) | 23.09.2011 | Examination requested [2011/44] | 18.09.2013 | Despatch of a communication from the examining division (Time limit: M06) | 17.03.2014 | Reply to a communication from the examining division | 19.05.2015 | Despatch of a communication from the examining division (Time limit: M06) | 20.11.2015 | Reply to a communication from the examining division | 29.03.2016 | Despatch of a communication from the examining division (Time limit: M06) | 29.09.2016 | Reply to a communication from the examining division | 13.10.2016 | Despatch of a communication from the examining division (Time limit: M06) | 12.04.2017 | Reply to a communication from the examining division | 04.07.2017 | Communication of intention to grant the patent | 26.10.2017 | Fee for grant paid | 26.10.2017 | Fee for publishing/printing paid | 26.10.2017 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP04775776.0 / EP1653976 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20040775776) is 27.08.2009 | Opposition(s) | 07.09.2018 | No opposition filed within time limit [2018/46] | Fees paid | Renewal fee | 04.03.2010 | Renewal fee patent year 03 | 04.03.2010 | Renewal fee patent year 04 | 04.03.2010 | Renewal fee patent year 05 | 04.03.2010 | Renewal fee patent year 06 | 04.03.2010 | Renewal fee patent year 07 | 23.02.2011 | Renewal fee patent year 08 | 24.02.2012 | Renewal fee patent year 09 | 27.02.2013 | Renewal fee patent year 10 | 27.02.2014 | Renewal fee patent year 11 | 26.02.2015 | Renewal fee patent year 12 | 26.02.2016 | Renewal fee patent year 13 | 27.02.2017 | Renewal fee patent year 14 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 18.02.2004 | AT | 06.12.2017 | CY | 06.12.2017 | CZ | 06.12.2017 | DK | 06.12.2017 | EE | 06.12.2017 | ES | 06.12.2017 | FI | 06.12.2017 | IT | 06.12.2017 | MC | 06.12.2017 | NL | 06.12.2017 | PT | 06.12.2017 | RO | 06.12.2017 | SE | 06.12.2017 | SI | 06.12.2017 | SK | 06.12.2017 | TR | 06.12.2017 | IE | 18.02.2018 | LU | 18.02.2018 | BE | 28.02.2018 | CH | 28.02.2018 | LI | 28.02.2018 | BG | 06.03.2018 | GR | 07.03.2018 | [2020/31] |
Former [2020/27] | HU | 18.02.2004 | |
AT | 06.12.2017 | ||
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
PT | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SI | 06.12.2017 | ||
SK | 06.12.2017 | ||
TR | 06.12.2017 | ||
IE | 18.02.2018 | ||
LU | 18.02.2018 | ||
BE | 28.02.2018 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2020/16] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SI | 06.12.2017 | ||
SK | 06.12.2017 | ||
TR | 06.12.2017 | ||
IE | 18.02.2018 | ||
LU | 18.02.2018 | ||
BE | 28.02.2018 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2019/12] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SI | 06.12.2017 | ||
SK | 06.12.2017 | ||
IE | 18.02.2018 | ||
LU | 18.02.2018 | ||
BE | 28.02.2018 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2019/09] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SI | 06.12.2017 | ||
SK | 06.12.2017 | ||
IE | 18.02.2018 | ||
LU | 18.02.2018 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/52] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SI | 06.12.2017 | ||
SK | 06.12.2017 | ||
LU | 18.02.2018 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/51] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
DK | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SK | 06.12.2017 | ||
CH | 28.02.2018 | ||
LI | 28.02.2018 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/44] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
MC | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SK | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/40] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
IT | 06.12.2017 | ||
NL | 06.12.2017 | ||
RO | 06.12.2017 | ||
SE | 06.12.2017 | ||
SK | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/38] | AT | 06.12.2017 | |
CZ | 06.12.2017 | ||
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
NL | 06.12.2017 | ||
SE | 06.12.2017 | ||
SK | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/37] | CZ | 06.12.2017 | |
EE | 06.12.2017 | ||
ES | 06.12.2017 | ||
FI | 06.12.2017 | ||
NL | 06.12.2017 | ||
SE | 06.12.2017 | ||
SK | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/34] | ES | 06.12.2017 | |
FI | 06.12.2017 | ||
NL | 06.12.2017 | ||
SE | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/24] | ES | 06.12.2017 | |
FI | 06.12.2017 | ||
SE | 06.12.2017 | ||
BG | 06.03.2018 | ||
GR | 07.03.2018 | ||
Former [2018/23] | ES | 06.12.2017 | |
FI | 06.12.2017 | ||
SE | 06.12.2017 | ||
GR | 07.03.2018 | ||
Former [2018/22] | ES | 06.12.2017 | |
FI | 06.12.2017 | Documents cited: | Search | [XP]US2004006007 (GOSSELIN GILLES [FR], et al) [XP] 1,3,12 * paragraph [0305] * * paragraph [0308] * * claims 3, 20, 30 *; | [X] - WAGA T ET AL, "SYNTHESIS AND BIOLOGICAL EVALUATON OF 4'-C-METHYL NUCLEOSIDES", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, (19960101), vol. 15, no. 1 - 03, ISSN 0732-8311, pages 287 - 304, XP000973778 [X] 1,3,12,16,21,22 * compounds 29, 31, 32, 40, 41, 42 * * table; page 294 * DOI: http://dx.doi.org/10.1080/07328319608002385 | [X] - HARAGUCHI KAZUHIRO ET AL, "Allylic Substitution of 3',4'-Unsaturated Nucleosides: Organosilicon-Base Stereoselective Access to 4'-C-Branched 2',3'-Didehydro-2',3'- dideoxyribonucleosides", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON.; US, (19960101), vol. 61, doi:10.1021/JO9516190, ISSN 0022-3263, pages 851 - 858, XP002247984 [X] 1 * page 854; compounds 26, 34, 36 * DOI: http://dx.doi.org/10.1021/jo9516190 | [X] - KATO K ET AL, "Enantio- and diastereoselective synthesis of 4'-alpha-substituted carbocyclic nucleosides", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, vol. 9, no. 6, ISSN 0957-4166, (19980327), pages 911 - 914, (19980327), XP027117867 [X] 1 * page 912; compound 5a * | [XP] - KAZUHIRO HARAGUCHI ET AL, "Synthesis of a Highly Active New Anti-HIV Agent 2',3'-Didehydro-3'-deoxy-4'-ethynylthymidine", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2003), vol. 13, pages 3775 - 3777, XP002614995 [XP] 3,9,11,12,16,21,22 * page 3776; compounds 13, 14, 15 * DOI: http://dx.doi.org/10.1016/J.BMCL.2003.07.009 | by applicant | US4880784 | US5179084 | US5491135 | US5532215 | US5821242 | US5891874 | US6114327 | US6180604 | US6232120 | US6240690 | US6316505 | US6316492 | - NOMURA ET AL., J MED. CHEM., (1999), vol. 42, pages 2901 - 2908 | - OHRUI ET AL., J MED. CHEM., (2000), vol. 43, pages 4516 - 4525 | - J. P. H. VERHEYDEN; J. G. MOFFATT, J ORG. CHEM., (1974), vol. 39, pages 3573 - 3579 | - B. V. JOSHI; C. B. REESE, TETRAHEDRON LETT., (1992), vol. 32, pages 2371 - 2374 | - KATO ET AL., CHEM. PHARM. BULL., (1999), vol. 47, pages 1256 - 1264 | - P. CALLANT; L. D'HAENES; M. VANDEWALLE, SYNTH. COMMUN., (1984), vol. 14, pages 155 - 161 | - I. GILLAIZEAU; I. M. LAGOJA; S. P. NOLAN; V. AUCAGNE; J. ROZENSKI; P. HERDEWIJN; L. A. AGROFOGLIO, EUR. J ORG. CHEM., (2003), pages 666 - 671 | - AUGUST, E. M.; M. E. MARONGIU; T. S. LIN; W. H. PRUSOF£, "Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus", BIOCHEM PHARMACOL, (1988), vol. 37, doi:doi:10.1016/0006-2952(88)90655-7, pages 4419 - 22, XP025515242 DOI: http://dx.doi.org/10.1016/0006-2952(88)90655-7 | - BRIDGES, E. G.; G. E. DUTSCHMAN; E. A. GULLEN; Y. C. CHENG, "Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus", BIOCHEM PHARMACOL, (1996), vol. 51, pages 731 - 6 | - BRINKMAN, K.; H. J. TER HOFSTEDE; D. M. BURGER; J. A. SMEITINK; P. P. KOOPMANS, "Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway", AIDS, (1998), vol. 12, pages 1735 - 44, XP008008118 | - BROWNE, M. J.; K. H. MAYER; S. B. CHAFEE; M. N. DUDLEY; M. R. POSNER; S. M. STEINBERG; K. K. GRAHAM; S. M. GELETKO; S. H. ZINNER;, "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial", JINFECT DIS, (1993), vol. 167, pages 21 - 9 | - CHEN, C. H.; Y. C. CHENG, "Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine", JBIOL CHEM, (1989), vol. 264, pages 11934 - 7 | - CHEN, C. H.; M. VAZQUEZ-PADUA; Y. C. CHENG, "Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity", MOL PHARMACOL, (1991), vol. 39, pages 625 - 8, XP008008115 | - "Thymidine Kinase from Blast Cells of Myelocytic Leukemia", CHENG, Y. C, Methods in Enzymology, ACADEMIC PRESS, (1978), vol. LI, pages 365 - 371 | - COATES, J. A.; N. CAMMACK; H. J. JENKINSON; A. J. JOWETT; M. I. JOWETT; B. A. PEARSON; C. R. PENN; P. L. ROUSE; K. C. VINER; J. M., "(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro", ANTIMICROB AGENTS CHEMOTHER, (1992), vol. 36, pages 733 - 9 | - COATES, J. A.; N. CAMMACK; H. J. JENKINSON; I. M. MUTTON; B. A. PEARSON; R. STORER; J. M. CAMERON; C. R. PENN, "The separated enantiomers of 2'-deoxy-3'- thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro", ANTIMICROB AGENTS CHEMOTHER, (1992), vol. 36, pages 202 - 5, XP000578441 | - DE CLERCQ, E., "HIV resistance to reverse transcriptase inhibitors", BIOCHEM PHARMACOL, (1994), vol. 47, doi:doi:10.1016/0006-2952(94)90001-9, pages 155 - 69, XP025553345 DOI: http://dx.doi.org/10.1016/0006-2952(94)90001-9 | - DOONG, S. L.; C. H. TSAI; R. F. SCHINAZI; D. C. LIOTTA; Y. C. CHENG, "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues", PROC NATL ACAD SCI U S A, (1991), vol. 88, doi:doi:10.1073/pnas.88.19.8495, pages 8495 - 9, XP002067580 DOI: http://dx.doi.org/10.1073/pnas.88.19.8495 | - DUTSCHMAN, G. E.; E. G. BRIDGES; S. H. LIU; E. GULLEN; X. GUO; M. KUKHANOVA; Y. C. CHENG, "Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro", ANTIMICROB AGENTS CHEMOTHER, (1998), vol. 42, pages 1799 - 804 | - FENG, J. Y.; A. A. JOHNSON; K. A. JOHNSON; K. S. ANDERSON, "Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs", JBIOL CHEM, (2001), vol. 276, pages 23 832 - 7 | - GELMON, K.; J. S. MONTANER; M. FANNING; J. R. SMITH; J. FALUTZ; C. TSOUKAS; J. GILL; G. WELLS; M. O'SHAUGHNESSY; M. WAINBERG ET AL, "Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial", AIDS, (1989), vol. 3, pages 555 - 61 | - GOSSELIN, G.; R. F. SCHINAZI; J. P. SOMMADOSSI; C. MATHE; M. C. BERGOGNE; A. M. AUBERTIN; A. KIRN; J. L. IMBACH, "Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro", ANTIMICROB AGENTS CHEMOTHER, (1994), vol. 3, no. 8, pages 1292 - 7 | - HAMAMOTO, Y.; H. NAKASHIMA; T. MATSUI; A. MATSUDA; T. UEDA; N. YAMAMOTO, "Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus", ANTIMICROB AGENTS CHEMOTHER, (1987), vol. 31, pages 907 - 10 | - HARAGUCHI, K.; S. TAKEDA; H. TANAKA; T. NITANDA; M. BABA; G. E. DUTSCHMAN; Y. C. CHENG, "Synthesis of a Highly Active New Anti-HIV Agent 2', 3'-Didehydro-3'deoxy-4'-ethynylthymidine", BIOORG MED CHEM SETTER, (2003), vol. 13, doi:doi:10.1016/J.BMCL.2003.07.009, pages 3775 - 3777, XP002660976 DOI: http://dx.doi.org/10.1016/J.BMCL.2003.07.009 | - JOHNSON, A. A.; A. S. RAY; J. HANES; Z. SUO; J. M. COLACINO; K. S. ANDERSON; K. A. JOHNSON, "Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase", JBIOL CHEM, (2001), vol. 276, pages 40847 - 57 | - LARDER, B. A., "Viral resistance and the selection of antiretroviral combinations", J ACQUIR IMMUNE DEFIC SYNDR HUM RETROVIROL, (1995), vol. 10, no. 1, pages 28 - 33 | - LARDER, B. A.; B. CHESEBRO; D. D. RICHMAN, "Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay", ANTIMICROB AGENTS CHEMOTHER, (1990), vol. 34, pages 436 - 41, XP009005039 | - LEE, L. S.; Y. C. CHENG, "Human deoxythymidine kinase. I.Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia", JBIOL CHEM, (1976), vol. 251, pages 2600 - 2604 | - LEWIS, W.; M. C. DALAKAS, "Mitochondrial toxicity of antiviral drugs", NAT MED, (1995), vol. 1, doi:doi:10.1038/nm0595-417, pages 417 - 22, XP000882362 DOI: http://dx.doi.org/10.1038/nm0595-417 | - LIN, T. S.; M. Z. LUO; M. C. LIU; S. B. PAI; G. E. DUTSCHMAN; Y. C. CHENG, "Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro", BIOCHEM PHARMACOL, (1994), vol. 47, pages 171 - 4 | - LIN, T. S.; M. Z. LUO; M. C. LIU; S. B. PAI; G. E. DUTSCHMAN; Y. C. CHENG, "Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV)", JMED CHEM, (1994), vol. 37, doi:doi:10.1021/jm00032a013, pages 798 - 803, XP002002033 DOI: http://dx.doi.org/10.1021/jm00032a013 | - LIN, T. S.; M. Z. LUO; M. C. LIU; Y. L. ZHU; E. GULLEN; G. E. DUTSCHMAN; Y. C. CHENG, "Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro", JMED CHEM, (1996), vol. 39, doi:doi:10.1021/jm950836q, pages 1757 - 9, XP001052613 DOI: http://dx.doi.org/10.1021/jm950836q | - LIN, T. S.; R. F. SCHINAZI; M. S. CHEN; E. KINNEY-THOMAS; W. H. PRUSOFF, "Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro", BIOCHEM PHARMACOL, (1987), vol. 36, doi:doi:10.1016/0006-2952(87)90287-5, pages 311 - 6, XP023737369 DOI: http://dx.doi.org/10.1016/0006-2952(87)90287-5 | - LIN, T. S.; R. F. SCHINAZI; W. H. PRUSOF£, "Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus", BIOCHEM PHARMACOL, (1987), vol. 36, doi:doi:10.1016/0006-2952(87)90253-X, pages 2713 - 8, XP023730619 DOI: http://dx.doi.org/10.1016/0006-2952(87)90253-X | - LU, Z. H.; R. ZHANG; R. B. DIASIO, "Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties", BIOCHEM PHARMACOL, (1993), vol. 46, doi:doi:10.1016/0006-2952(93)90505-Q, pages 945 - 52, XP023757565 DOI: http://dx.doi.org/10.1016/0006-2952(93)90505-Q | - MAAG, H.; R. M. RYDZEWSKI; M. J. MCROBERTS; D. CRAWFORD-RUTH; J. P. VERHEYDEN; E. J. PRISBE, "Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides", JMED CHEM, (1992), vol. 35, doi:doi:10.1021/jm00086a013, pages 1440 - 51, XP002277180 DOI: http://dx.doi.org/10.1021/jm00086a013 | - MEDINA, D. J.; C. H. TSAI; G. D. HSIUNG; Y. C. CHENG, "Comparison of Mitochondrial Morphology, Mitochondrial DNA Content, and Cell Viability in Cultured Cells Treated with Three Anti-Human Immunodeficiency Virus Dideoxynucleosides", ANTIMICROB AGENTS CHEMOTHER, (1994), vol. 38, pages 1824 - 1828, XP002213604 | - MELLORS, J. W.; G. E. DUTSCHMAN; G. J. IM; E. TRAMONTANO; S. R. WINKLER; Y. C. CHENG, "In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase", MOL PHARMACOL, (1992), vol. 41, pages 446 - 51 | - O-YANG, C.; H. Y. WU; B. FRASER-SMITH; K. A. M. WALKER, "Synthesis of 4'-Cyanothymidine and Analogs as Potent Inhibitors of HIV", TETRAHEDRON LETTERS, (1992), vol. 33, doi:doi:10.1016/S0040-4039(00)77667-2, pages 37 - 40, XP002969549 DOI: http://dx.doi.org/10.1016/S0040-4039(00)77667-2 | - "Disruption of Energy Metabolism and Mitochondrial Function", PARKER, W. B.; Y. C. CHENG, Neurotoxicology: Approaches and Methods, ACADEMIC PRESS INC., (1995), pages 483 - 490 | - PARKER, W. B.; Y. C. CHENG, "Mitochondrial Toxicity of Antiviral Nucleoside Analogs", THE JOURNAL OF HIH REASEARCH, (1994), vol. 6, pages 57 - 61 | - RICHMAN, D. D., "Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents", ANTIMICROB AGENTS CHEMOTHER, (1993), vol. 37, pages 1207 - 13 | - RICHMAN, D. D.; M. A. FISCHL; M. H. GRIECO; M. S. GOTTLIEB; P. A. VOLBERDING; O. L. LASKIN; J. M. LEEDOM; J. E. GROOPMAN; D. MILDV, "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial", NENGL JMED, (1987), vol. 317, pages 192 - 7 | - SCHINAZI, R. F.; C. K. CHU; A. PECK; A. MCMILLAN; R. MATHIS; D. CANNON; L. S. JEONG; J. W. BEACH; W. B. CHOI; S. YEOLA ET AL., "Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes", ANTIMICROB AGENTS CHEMOTHER, (1992), vol. 36, pages 672 - 6, XP000578440 | - SOMMADOSSI, J. P.; Z. ZHOU; M. J. HITCHCOCK; H. M. MCCLURE; M. EL KOUNI; E. CRETTON, "Catabolism of 2',3'-Didehydro-2',3-DideoxyThymidine (D4T) in Isolated Hepatocytes and in Rhesus Monkeys", PROC.ANNU. MEETINGAMERICAN CANCER RESEARCH, (1992), vol. 33, page A3253 | - YARCHOAN, R.; J. M. PLUDA; R. V. THOMAS; H. MITSUYA; P. BROUWERS; K. M. WYVILL; N. HARTMAN; D. G. JOHNS; S. BRODER, "Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex", LANCET, (1990), vol. 336, pages 526 - 9 |